vs

Side-by-side financial comparison of Cytek Biosciences, Inc. (CTKB) and XPEL, Inc. (XPEL). Click either name above to swap in a different company.

XPEL, Inc. is the larger business by last-quarter revenue ($122.3M vs $62.1M, roughly 2.0× Cytek Biosciences, Inc.). XPEL, Inc. runs the higher net margin — 11.0% vs -70.9%, a 81.9% gap on every dollar of revenue. On growth, XPEL, Inc. posted the faster year-over-year revenue change (13.7% vs 8.1%). XPEL, Inc. produced more free cash flow last quarter ($1.6M vs $-1.8M). Over the past eight quarters, Cytek Biosciences, Inc.'s revenue compounded faster (17.7% CAGR vs 16.5%).

Cytek Biosciences, Inc. develops, manufactures and sells high-performance flow cytometry systems, associated reagents and analysis software. Its solutions serve life science research, clinical diagnostics and biopharmaceutical sectors, with a global customer base across North America, Europe and the Asia-Pacific region.

XPEL, Inc. is a global provider of high-performance surface protection solutions primarily for automotive use. Core offerings include paint protection films, window tints, and ceramic coatings, serving vehicle owners, dealerships, and professional installers across North America, Europe, and Asia Pacific.

CTKB vs XPEL — Head-to-Head

Bigger by revenue
XPEL
XPEL
2.0× larger
XPEL
$122.3M
$62.1M
CTKB
Growing faster (revenue YoY)
XPEL
XPEL
+5.6% gap
XPEL
13.7%
8.1%
CTKB
Higher net margin
XPEL
XPEL
81.9% more per $
XPEL
11.0%
-70.9%
CTKB
More free cash flow
XPEL
XPEL
$3.4M more FCF
XPEL
$1.6M
$-1.8M
CTKB
Faster 2-yr revenue CAGR
CTKB
CTKB
Annualised
CTKB
17.7%
16.5%
XPEL

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
CTKB
CTKB
XPEL
XPEL
Revenue
$62.1M
$122.3M
Net Profit
$-44.1M
$13.4M
Gross Margin
52.9%
41.9%
Operating Margin
-9.0%
12.7%
Net Margin
-70.9%
11.0%
Revenue YoY
8.1%
13.7%
Net Profit YoY
-557.1%
50.7%
EPS (diluted)
$0.48

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CTKB
CTKB
XPEL
XPEL
Q4 25
$62.1M
$122.3M
Q3 25
$52.3M
$125.4M
Q2 25
$45.6M
$124.7M
Q1 25
$41.5M
$103.8M
Q4 24
$57.5M
$107.5M
Q3 24
$51.5M
$112.9M
Q2 24
$46.6M
$109.9M
Q1 24
$44.9M
$90.1M
Net Profit
CTKB
CTKB
XPEL
XPEL
Q4 25
$-44.1M
$13.4M
Q3 25
$-5.5M
$12.9M
Q2 25
$-5.6M
$16.3M
Q1 25
$-11.4M
$8.6M
Q4 24
$9.6M
$8.9M
Q3 24
$941.0K
$14.9M
Q2 24
$-10.4M
$15.0M
Q1 24
$-6.2M
$6.7M
Gross Margin
CTKB
CTKB
XPEL
XPEL
Q4 25
52.9%
41.9%
Q3 25
52.7%
41.8%
Q2 25
52.3%
42.9%
Q1 25
48.6%
42.3%
Q4 24
58.5%
40.6%
Q3 24
56.3%
42.5%
Q2 24
54.6%
43.5%
Q1 24
51.3%
42.0%
Operating Margin
CTKB
CTKB
XPEL
XPEL
Q4 25
-9.0%
12.7%
Q3 25
-17.6%
13.4%
Q2 25
-23.3%
15.5%
Q1 25
-36.1%
10.7%
Q4 24
5.2%
11.5%
Q3 24
-8.2%
16.3%
Q2 24
-18.3%
17.5%
Q1 24
-23.9%
10.2%
Net Margin
CTKB
CTKB
XPEL
XPEL
Q4 25
-70.9%
11.0%
Q3 25
-10.5%
10.3%
Q2 25
-12.2%
13.1%
Q1 25
-27.5%
8.3%
Q4 24
16.8%
8.3%
Q3 24
1.8%
13.2%
Q2 24
-22.4%
13.7%
Q1 24
-13.8%
7.4%
EPS (diluted)
CTKB
CTKB
XPEL
XPEL
Q4 25
$0.48
Q3 25
$0.47
Q2 25
$0.59
Q1 25
$0.31
Q4 24
$0.33
Q3 24
$0.54
Q2 24
$0.54
Q1 24
$0.24

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CTKB
CTKB
XPEL
XPEL
Cash + ST InvestmentsLiquidity on hand
$90.9M
$50.9M
Total DebtLower is stronger
Stockholders' EquityBook value
$341.7M
$280.3M
Total Assets
$461.5M
$382.5M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CTKB
CTKB
XPEL
XPEL
Q4 25
$90.9M
$50.9M
Q3 25
$93.3M
$64.5M
Q2 25
$75.5M
$49.6M
Q1 25
$95.3M
$23.5M
Q4 24
$98.7M
$22.1M
Q3 24
$162.3M
$21.0M
Q2 24
$177.9M
$15.0M
Q1 24
$168.8M
$8.6M
Stockholders' Equity
CTKB
CTKB
XPEL
XPEL
Q4 25
$341.7M
$280.3M
Q3 25
$378.6M
$269.3M
Q2 25
$377.6M
$255.7M
Q1 25
$379.6M
$235.5M
Q4 24
$395.7M
$225.5M
Q3 24
$385.5M
$218.7M
Q2 24
$389.1M
$201.9M
Q1 24
$392.6M
$186.4M
Total Assets
CTKB
CTKB
XPEL
XPEL
Q4 25
$461.5M
$382.5M
Q3 25
$494.9M
$387.7M
Q2 25
$493.3M
$318.1M
Q1 25
$482.6M
$294.8M
Q4 24
$499.5M
$285.6M
Q3 24
$491.2M
$273.0M
Q2 24
$483.7M
$261.8M
Q1 24
$492.1M
$258.5M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CTKB
CTKB
XPEL
XPEL
Operating Cash FlowLast quarter
$-771.0K
$2.7M
Free Cash FlowOCF − Capex
$-1.8M
$1.6M
FCF MarginFCF / Revenue
-2.9%
1.3%
Capex IntensityCapex / Revenue
1.6%
0.9%
Cash ConversionOCF / Net Profit
0.20×
TTM Free Cash FlowTrailing 4 quarters
$-8.8M
$62.9M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CTKB
CTKB
XPEL
XPEL
Q4 25
$-771.0K
$2.7M
Q3 25
$-3.9M
$33.2M
Q2 25
$108.0K
$27.9M
Q1 25
$-125.0K
$3.2M
Q4 24
$2.0M
$6.3M
Q3 24
$13.2M
$19.6M
Q2 24
$6.2M
$26.9M
Q1 24
$4.0M
$-5.0M
Free Cash Flow
CTKB
CTKB
XPEL
XPEL
Q4 25
$-1.8M
$1.6M
Q3 25
$-4.6M
$32.2M
Q2 25
$-1.5M
$26.9M
Q1 25
$-974.0K
$2.2M
Q4 24
$1.1M
$4.7M
Q3 24
$12.2M
$18.3M
Q2 24
$5.2M
$25.1M
Q1 24
$3.4M
$-7.0M
FCF Margin
CTKB
CTKB
XPEL
XPEL
Q4 25
-2.9%
1.3%
Q3 25
-8.7%
25.6%
Q2 25
-3.2%
21.6%
Q1 25
-2.3%
2.1%
Q4 24
1.9%
4.4%
Q3 24
23.7%
16.2%
Q2 24
11.0%
22.8%
Q1 24
7.6%
-7.7%
Capex Intensity
CTKB
CTKB
XPEL
XPEL
Q4 25
1.6%
0.9%
Q3 25
1.3%
0.8%
Q2 25
3.5%
0.8%
Q1 25
2.0%
1.0%
Q4 24
1.6%
1.5%
Q3 24
2.0%
1.1%
Q2 24
2.3%
1.6%
Q1 24
1.3%
2.2%
Cash Conversion
CTKB
CTKB
XPEL
XPEL
Q4 25
0.20×
Q3 25
2.56×
Q2 25
1.71×
Q1 25
0.38×
Q4 24
0.21×
0.71×
Q3 24
14.05×
1.31×
Q2 24
1.79×
Q1 24
-0.74×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

CTKB
CTKB

Products$46.6M75%
Services$15.5M25%

XPEL
XPEL

Products$90.9M74%
Service Revenue Installation Labor$23.8M19%
Service Revenue Cutbank Credits$4.1M3%
Service Revenue Software$2.2M2%

Related Comparisons